NASDAQ:SYRE | Free Cash Flow | Spyre Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2014-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$57.37M
2025-12-31-$44.58M
2025-03-31-$40.99M
2024-12-31-$37.2M
2024-03-31-$28.54M
2023-12-31-$31.04M$0.00-$31.04M
2023-03-31-$17.63M
2022-12-31-$18.14M$0.00-$18.14M
2022-03-31-$26.26M$37,000.00-$26.3M
2021-12-31-$19.27M$0.00-$19.27M
2021-03-31-$19.53M$450,000.00-$19.98M
2020-12-31-$17.13M$1M-$18.13M
2020-03-31-$21.69M$1.39M-$23.08M
2019-12-31-$16.29M$1.17M-$17.47M
2019-03-31-$15.81M$118,000.00-$15.93M
2018-12-31-$7.2M$203,000.00-$7.4M
2018-03-31-$7.45M$83,000.00-$7.53M
2017-12-31-$5.87M$191,000.00-$6.06M
2017-03-31-$5.43M$271,000.00-$5.7M
2016-12-31-$4.36M$121,000.00-$4.48M
2016-03-31-$3.99M$2,000.00-$3.99M
2015-12-31-$833,000.00$40,000.00-$873,000.00
2015-03-31-$2.48M$10,000.00-$2.49M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$169.25M
2024-12-31-$157.41M$0.00-$157.41M
2023-12-31-$99.91M$0.00-$99.91M
2022-12-31-$80.14M$38,000.00-$80.18M
2021-12-31-$53.72M$573,000.00-$54.29M
2020-12-31-$75.78M$4.28M-$80.06M
2019-12-31-$65.69M$1.49M-$67.18M
2018-12-31-$32.19M$422,000.00-$32.62M
2017-12-31-$24.62M$619,000.00-$25.23M
2016-12-31-$18.84M$212,000.00-$19.05M
2015-12-31-$10.98M$208,000.00-$11.19M
2014-12-31-$7.34M$181,000.00-$7.52M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.